2026 CLL Update: Game Changer Therapies for Oncologists?

Описание: In this expert discussion from Oncology Tube, Dr. Allison Reichl (UC Irvine) breaks down the most important CLL treatment updates from ASH 2025 that will shape practice in 2026.
She covers:

Time-limited regimens (CLL17 trial) vs continuous BTK inhibitors
Advantages and challenges of fixed-duration therapy
Why unfit patients may benefit most from pushing through time-limited approaches
Pirtobrutinib's strong performance in BRUIN CLL-313 and BRUIN CLL-314
Significantly lower atrial fibrillation rates compared to ibrutinib
Critical sequencing considerations — when to use pirtobrutinib first-line vs as salvage

Key takeaway: Pirtobrutinib shows game-changing potential with improved cardiovascular safety, but first-line use may impact future covalent BTKi options.
Perfect for hematologists, oncologists, fellows, and anyone following the evolving CLL landscape.
Timestamps:
00:00 – Introduction & Why Time-Limited Regimens Matter
00:36 – Challenges of Time-Limited Therapy
00:50 – Best Candidates: Unfit Patients
01:06 – CLL17 Trial: Non-Inferiority & Early Data
01:20 – MRD Benefit & Combination Therapy Questions
01:48 – VI Regimen: Practical Insights & Approval Status
02:30 – BRUIN CLL-313: Pirtobrutinib vs Chemoimmunotherapy
03:00 – Cardiovascular Safety Advantages
03:15 – Sequencing Discussion: Where Does Pirtobrutinib Fit?
03:34 – Caution on First-Line Pirtobrutinib Use
03:52 – BRUIN CLL-314: Pirtobrutinib vs Ibrutinib
04:20 – Final Takeaways & Closing

Video interviews to be posted from this event at these websites...
https://oncologytube.com/tag/moasc/
https://moasc.org/

About OncologyTube.com:
OncologyTube.com is a free video-sharing platform dedicated to oncology professionals, offering cancer research updates through videos, audio, PowerPoint presentations, and more. Visit OncologyTube.com for a detailed web post on this and many other cancer topics and oncology insights.

Follow OncologyTube:
eNewsletter: https://oncologytube.com/newsletter/
Twitter: / oncologytube
LinkedIn: / oncologytube-com
Facebook: / oncologytube
Instagram: / oncologytube
YouTube: / oncologytube

Connect with Us:
Share your thoughts in the comments! Join the discussion.